<div id="readability-page-1"><p>In a report released today, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on Trevi Therapeutics, with a price target of <span id="expert-recommendation-target">$18.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Samimy covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, Viking Therapeutics, and RegenXBio. According to TipRanks, Samimy has an average return of <span>17.1%</span> and a 50.79% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevi Therapeutics with a $22.14 average price target.</p></div>

TRVI

ARKG

<p>Stifel Nicolaus analyst Annabel Samimy has maintained a Buy rating on Trevi Therapeutics (TRVI) with a price target of $18.00. The analyst has an average return of 17.1% and a success rate of 50.79% on her stock recommendations. The overall analyst consensus for Trevi Therapeutics is a Strong Buy, with an average price target of $22.14.</p>

Tip Ranks

Trevi Therapeutics

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VG Health

VanEck Biotech ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Stifel Financial

Viking Therap

Regenxbio

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)